Kenvue (KVUE) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$15.4B

Revenue (quarter)

$4.0B

Revenue growth (year over year)

+3.02%

Gross profit (trailing twelve months)

$9.0B

Gross margin

58.19%

Net income (trailing twelve months)

$1.7B

Net income (quarter)

$456.0M

Net income growth (year over year)

+8.57%

Net margin

10.76%

Return on equity

15.58%

EPS (trailing twelve months)

$0.86

Book value per share

$5.50

P/E (trailing twelve months)

21.63

Price to book

3.40

Debt to assets

60.53%

Payout ratio

107.59%

Dividend yield

5.58%

Company profile

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

• Is Kenvue (KVUE) profitable?

  Yes. Kenvue earned $1.7B in net income over the trailing twelve months, a net margin of 10.76%.

• How much revenue does Kenvue (KVUE) make?

  Kenvue generated $15.4B in revenue over the trailing twelve months, up 3.02% year over year.

• What is KVUE's P/E ratio?

  Kenvue trades at 21.6 times trailing twelve-month earnings, on an EPS of $0.86.

• How do I buy stock in Kenvue (KVUE)?

  KVUE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.